Skip to main content

Breast Cancer Research and Treatment

Ausgabe 2/2021

Inhalt (30 Artikel)

Body composition and breast cancer risk and treatment: mechanisms and impact

  • Review

Toshiaki Iwase, Xiaoping Wang, Tushaar Vishal Shrimanker, Mikhail G. Kolonin, Naoto T. Ueno

Oleuropein is a natural inhibitor of PAI-1-mediated proliferation in human ER-/PR- breast cancer cells

  • Preclinical study

Elena E. Tzekaki, George Geromichalos, Sophia N. Lavrentiadou, Maria P. Tsantarliotou, Anastasia A. Pantazaki, Angelos Papaspyropoulos

FOXA1 is a determinant of drug resistance in breast cancer cells

  • Open Access
  • Preclinical study

Uttom Kumar, Anastasia Ardasheva, Zimam Mahmud, R. Charles Coombes, Ernesto Yagüe

Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients

  • Open Access
  • Preclinical study

Peng Qi, Yu Yang, Qian-ming Bai, Tian Xue, Min Ren, Qian-lan Yao, Wen-tao Yang, Xiao-yan Zhou

Can we rely on surgical clips placed during oncoplastic breast surgery to accurately delineate the tumor bed for targeted breast radiotherapy?

  • Preclinical study

Ghada Aldosary, Jean-Michel Caudrelier, Angel Arnaout, Lynn Chang, Tabitha Tse, Claire Foottit, Jiheon Song, Jason Belec, Eric Vandervoort

Comprehensive analysis of the homeobox family genes in breast cancer demonstrates their similar roles in cancer and development

  • Preclinical study

Ayako Nakashoji, Tetsu Hayashida, Shigeo Yamaguchi, Yuko Kawai, Masayuki Kikuchi, Takamichi Yokoe, Aiko Nagayama, Tomoko Seki, Maiko Takahashi, Yuko Kitagawa

Heregulin-induced cell migration is prevented by trastuzumab and trastuzumab-emtansine in HER2+ breast cancer

  • Preclinical study

Joselina Magali Mondaca, Ana Carla Castro Guijarro, Marina Inés Flamini, Angel Matias Sanchez

Analysis of tumor nuclear features using artificial intelligence to predict response to neoadjuvant chemotherapy in high-risk breast cancer patients

  • Preclinical study

David W. Dodington, Andrew Lagree, Sami Tabbarah, Majid Mohebpour, Ali Sadeghi-Naini, William T. Tran, Fang-I Lu

Multiethnic PDX models predict a possible immune signature associated with TNBC of African ancestry

  • Preclinical study

Evelyn M. Jiagge, Peter J. Ulintz, Shukmei Wong, Sean P. McDermott, Sabrina I. Fossi, Tahra K. Suhan, Mark J. Hoenerhoff, Jessica M. Bensenhaver, Barbara Salem, Michele Dziubinski, Joseph K. Oppong, Francis Aitpillah, Kyei Ishmael, Ernest Osei-Bonsu, Ernest Adjei, Awuah Baffour, Jessica Aldrich, Ahmet Kurdoglu, Kurt Fernando, David W. Craig, Jeff M. Trent, Jun Li, Dhananjay Chitale, Lisa A. Newman, John D. Carpten, Max S. Wicha, Sofia D. Merajver

Validation of prognostic significance of the proposed uniform classification framework in neuroendocrine neoplasms of the breast

  • Preclinical study

Libo Yang, Madhuchhanda Roy, Heather Lin, Yu Shen, Constance Albarracin, Lei Huo, Hui Chen, Bing Wei, Isabelle Bedrosian, Hong Bu, Yun Wu

Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials

  • Open Access
  • Clinical trial

Matthew P. Goetz, Meena Okera, Hans Wildiers, Mario Campone, Eva-Maria Grischke, Luis Manso, Valérie A. M. André, Nadia Chouaki, Belén San Antonio, Masakazu Toi, George W. Sledge Jr.

Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation

  • Clinical trial

Molly B. Moravek, Rafael Confino, Angela K. Lawson, Kristin N. Smith, Ralph R. Kazer, Susan C. Klock, William J. Gradishar, Jacqueline S. Jeruss, Mary Ellen Pavone

New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12)

  • Clinical trial

Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki Chung, Kyung Su Kim, Won Sup Yoon, Jin Hee Kim, Jihye Cha, Yoon Kyeong Oh, In Ah Kim

Prediction of axillary nodal burden in patients with invasive lobular carcinoma using MRI

  • Clinical trial

Su Min Ha, Jung Min Chang, Soo-Yeon Kim, Su Hyun Lee, Eun Sil Kim, Yeon Soo Kim, Nariya Cho, Woo Kyung Moon

Residual risk stratification of Taiwanese breast cancers following curative therapies with the extended concurrent genes signature

  • Clinical trial

Ching-Shui Huang, Tzu-Pin Lu, Chih-Yi Liu, Chi-Jung Huang, Jen-Hwey Chiu, Yen-Jen Chen, Ling-Ming Tseng, Chi-Cheng Huang

Myosteatosis evaluation using erector spinae and psoas muscles to predict adverse events during adjuvant chemotherapy for breast cancer

  • Clinical trial

G. F. P. Aleixo, H. Yu, Y. T. Chen, K. A. Nyrop, R. J. Louie, A. M. Deal, S. S. Shachar, H. B. Muss, G. R. Williams

Patterns of de-novo metastasis and breast cancer-specific mortality by race and molecular subtype in the SEER population-based dataset

  • Epidemiology

Swati Sakhuja, April Deveaux, Lauren E. Wilson, Neomi Vin-Raviv, Dongyu Zhang, Dejana Braithwaite, Sean Altekruse, Tomi Akinyemiju

COVID-19 and breast cancer at a Regional Breast Centre: our flexible approach during the pandemic

Lina Cadili, Kristin DeGirolamo, Elaine McKevitt, Carl J. Brown, Christopher Prabhakar, Jin-Si Pao, Carol Dingee, Amy Bazzarelli, Rebecca Warburton

Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer

  • Epidemiology

Ipshita Prakash, Samantha M. Thomas, Rachel A. Greenup, Jennifer K. Plichta, Laura H. Rosenberger, Terry Hyslop, Oluwadamilola M. Fayanju

Ductal carcinoma in situ in patients younger than 30 years: differences in adjuvant endocrine therapy and outcomes

  • Epidemiology

Sasha R. Halasz, Thomas O’Keefe, Anne M. Wallace, Sarah L. Blair

Relationship of circulating immune cells with lifestyle factors and cancer recurrence in early-stage breast cancer

  • Epidemiology

Eric Xie, Maya M. Lapinski, Sarah Talamantes, Bareng A. S. Nonyane, Maria Cristina Figueroa Magalhães, Kala Visvanathan, Antonio C. Wolff, Cesar A. Santa-Maria

Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series

  • Open Access
  • Brief Report

Jasmine Sukumar, Mahmoud Kassem, Doreen Agnese, Robert Pilarski, Bhuvaneswari Ramaswamy, Kevin Sweet, Sagar Sardesai

(Ex-)breast cancer patients with (pre-existing) symptoms of anxiety and/or depression experience higher barriers to contact health care providers during the COVID-19 pandemic

Dieuwke R. Mink van der Molen, Claudia A. Bargon, Marilot C. T. Batenburg, Roxanne Gal, Danny A. Young-Afat, Lilianne E. van Stam, Iris E. van Dam, Femke van der Leij, Inge O. Baas, Miranda F. Ernst, Wiesje Maarse, Nieke Vermulst, Ernst J. P. Schoenmaeckers, Thijs van Dalen, Rhodé M. Bijlsma, Annemiek Doeksen, Helena M. Verkooijen

Correction to: Behavior of metastatic breast cancer according to subtype

  • Correction

Margot Van Mechelen, Anke Van Herck, Kevin Punie, Ines Nevelsteen, Ann Smeets, Patrick Neven, Caroline Weltens, Sileny Han, Adriaan Vanderstichele, Giuseppe Floris, Jean-Pierre Lobelle, Hans Wildiers

Neu im Fachgebiet Onkologie

Körperlich fitte Krebskranke leben länger

Krebspatienten, auch und vor allem solche in fortgeschrittenen Stadien, profitieren offenbar von guter körperlicher Verfassung. Hohe Muskelkraft und kardiorespiratorische Fitness sind laut Ergebnissen einer Metaanalyse mit geringerer Mortalität assoziiert.

Kein (großer) Schutz vor Kolorektalkarzinom-Rezidiven durch ASS

Die erste Phase-3-Studie zum Nutzen von ASS in der adjuvanten Therapie des kolorektalen Karzinoms ist negativ verlaufen. Das abschließende Urteil über eine Sekundärprävention mit ASS ist trotzdem noch nicht gefallen.

Frühe CLL-Therapie: BTK-Hemmer verlängert EFS und PFS, aber nicht OS

Auch nach sechs Jahren ergibt sich kein Überlebensvorteil einer Therapie mit dem BTK-Hemmer Ibrutinib für Menschen mit frühem CLL-Stadium und erhöhtem Progressionsrisiko. Die Progressionsrate wird mit der Behandlung jedoch um über 80% gesenkt.

Adjuvantes Atezolizumab ohne Nutzen bei frühem TNBC

Patientinnen mit frühem triple-negativem Brustkrebs profitieren nach der Operation offenbar nicht von einer Zugabe des PD-L1-Hemmers Atezolizumab zur adjuvanten Standardchemotherapie. Die Studie, die das untersucht hat, wurde vorzeitig abgebrochen. Was könnte die schlechte Wirksamkeit erklären?

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.